Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization: a systematic review and meta-analysis.

[1]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[2]  M. Nazzaro,et al.  3-year clinical outcome of patients with chronic total occlusion treated with drug-eluting stents. , 2009, JACC. Cardiovascular interventions.

[3]  J. Spertus,et al.  Chronic total occlusion angioplasty in the United States. , 2009, JACC. Cardiovascular interventions.

[4]  G. Werner,et al.  Management of total restenotic occlusions. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[5]  J. Lindbäck,et al.  Outcome of drug-eluting versus bare-metal stenting used according to on- and off-label criteria. , 2009, Journal of the American College of Cardiology.

[6]  Ya‐Ling Han,et al.  Long-term outcomes of drug-eluting versus bare-metal stent implantation in patients with chronic total coronary artery occlusions. , 2009, Chinese medical journal.

[7]  E. Pucci,et al.  Clinical outcome of patients with chronic total occlusion treated with drug-eluting stents. , 2009, International journal of cardiology.

[8]  Sunil V. Rao,et al.  Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: the ACROSS/TOSCA-4 (Approaches to Chronic Occlusions With Sirolimus-Eluting Stents/Total Occlusion Study of Coronary Arteries-4) trial. , 2009, JACC: Cardiovascular Interventions.

[9]  G. Stone,et al.  Abstract 2518: Clinical and Angiographic Outcomes after Percutaneous Revascularization of Chronic Total Occlusions with Bare-Metal and Drug-Eluting Stents: 3-year Follow-up Results from an International Multicenter CTO Registry , 2008 .

[10]  F. Alfonso.  The "vulnerable" stent why so dreadful? , 2008, Journal of the American College of Cardiology.

[11]  F. Amico,et al.  Two-year clinical follow up of coronary drug-eluting stent in patients at high risk for coronary restenosis. , 2008, The Journal of invasive cardiology.

[12]  P. Serruys,et al.  Three‐year clinical outcomes after coronary stenting of chronic total occlusion using sirolimus‐eluting stents: Insights from the rapamycin‐eluting stent evaluated at rotterdam cardiology hospital—(RESEARCH) registry , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[13]  A. Er,et al.  Comparison between bare metal stents and drug eluting stents for the treatment of chronic total occlusion , 2007 .

[14]  J. Granada,et al.  Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. , 2007, JAMA.

[15]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.

[16]  Bernard Chevalier,et al.  European perspective in the recanalisation of Chronic Total Occlusions (CTO): consensus document from the EuroCTO Club. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[17]  H. Bøtker,et al.  Sirolimus versus bare metal stent implantation in patients with total coronary occlusions: subgroup analysis of the Stenting Coronary Arteries in Non-Stress/Benestent Disease (SCANDSTENT) trial. , 2006, American heart journal.

[18]  B. Rensing,et al.  Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): A Randomized Comparison of Bare Metal Stent Implantation With Sirolimus-Eluting Stent Implantation for the Treatment of Total Coronary Occlusions , 2006, Circulation.

[19]  G. Parodi,et al.  Drug‐eluting stent‐supported percutaneous coronary intervention for chronic total coronary occlusion , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[20]  Gary S. Mintz,et al.  Percutaneous Recanalization of Chronically Occluded Coronary Arteries: A Consensus Document Part II , 2005, Circulation.

[21]  I. Iakovou,et al.  Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions. , 2005, European heart journal.

[22]  J. Bae,et al.  Impact of sirolimus-eluting stent on the outcome of patients with chronic total occlusions. , 2005, The American journal of cardiology.

[23]  H. Figulla,et al.  Determinants of target vessel failure in chronic total coronary occlusions after stent implantation. The influence of collateral function and coronary hemodynamics. , 2003, Journal of the American College of Cardiology.

[24]  F. Verheugt,et al.  Influence of planned six-month follow-up angiography on late outcome after percutaneous coronary intervention: a randomized study. , 2001, Journal of the American College of Cardiology.

[25]  K. Teo,et al.  Primary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). , 1999, Circulation.

[26]  C. Vassanelli,et al.  Stent implantation versus balloon angioplasty in chronic coronary occlusions: results from the GISSOC trial. Gruppo Italiano di Studio sullo Stent nelle Occlusioni Coronariche. , 1998, Journal of the American College of Cardiology.

[27]  J. Bourke,et al.  Surgery for control of recurrent life-threatening ventricular tachyarrhythmias within 2 months of myocardial infarction. , 1990, Journal of the American College of Cardiology.

[28]  J. Higgins.  Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[29]  T. Shaburishvili,et al.  [Comparison between bare metal stents and drug eluting stents for the treatment of chronic total occlusion]. , 2007, Georgian medical news.

[30]  Antonio Colombo,et al.  Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I. , 2005, Circulation.

[31]  R. Goeree,et al.  Safety and effectiveness of drug-eluting and bare-metal stents for patients with off- and on-label indications. , 2009, Journal of the American College of Cardiology.